Name: Setmelanotide (RM-493)
Brand: Selleck Chemicals
SKU: E1002
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: Purity: 99.76%

99.76

Related Targets	CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas
Other Melanocortin Receptor Inhibitors	JNJ-10229570 α-MSH Bremelanotide Acetate

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (89.5 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : 100 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5mg/ml (4.48mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.25mg/ml (0.22mM)	Taking the 1 mL working solution as an example, add 50 μL of 5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (4.48mM)	Taking the 1 mL working solution as an example, add 50 μL 100 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.650mg/ml (1.48mM)	Taking the 1 mL working solution as an example, add 50 μL 33 mg/ml clarified DMSO stock solution to 950 μL corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	1117.31	Formula	C₄₉H₆₈N₁₈O₉S₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	920014-72-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	BIM-22493, CAM 4072			SMILES	CC1NC(=O)C(CSSCC(NC(=O)C(CC2=C[NH]C3=CC=CC=C23)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC5=CN=C[NH]5)NC1=O)C(N)=O)NC(=O)C(CCCN=C(N)N)NC(C)=O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	MC4R 0.27 nM(EC50) MC4R 2.1 nM(Ki)
In vitro	Setmelanotide (RM-493) decreases TNF-α/IFN-γ-induced chemokine expression in astrocytes and increases IL-6 and IL-11 mRNA and protein secretion via MC4R. It induces CREB phosphorylation in astrocytes, and this compound treated astrocytes secrete factors that are able to modulate macrophage polarization into an anti-inflammatory phenotype.
In vivo	Setmelanotide (RM-493) co-treatment enhances weight loss in DIO mice and hypothalamic Glp-1r expression is higher in mice treated with the combination therapy after both acute and chronic treatment. Adjunctive administration of this compound improves glucose tolerance and insulin sensitivity, lowers fasting levels of glucose and insulin and decreases cholesterol levels beyond what can be achieved with the corresponding mono-therapies.
References	[1] https://pubmed.ncbi.nlm.nih.gov/25675384/ [2] https://pubmed.ncbi.nlm.nih.gov/31636637/ [3] https://pubmed.ncbi.nlm.nih.gov/25652173/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-29)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07674290	RECRUITING	Bardet Biedl Syndrome (BBS); Bardet Biedl Syndrome; Bardet-Biedl Syndrome (BBS); Alstrom Syndrome	Tom Hühne	2023-01-01	PHASE4
NCT07496463	ENROLLING_BY_INVITATION	Pseudohypoparathyroidism Type 1a; Obesity	Massachusetts General Hospital	2026-07-21	PHASE2
NCT06760546	RECRUITING	Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Hormone Deficiency; Pituitary Stalk Interruption Syndrome	Rhythm Pharmaceuticals, Inc.	2025-09-23	PHASE3
NCT06772597	ACTIVE_NOT_RECRUITING	Prader-Willi Syndrome; Obesity; Hyperphagia	Rhythm Pharmaceuticals, Inc.	2025-03-04	PHASE2
NCT06596135	COMPLETED	Obesity Associated With Defects in Leptin-melanocortin Pathway	Rhythm Pharmaceuticals, Inc.	2024-10-21	PHASE3
NCT05093634	COMPLETED	Obesity; Genetic Obesity	Rhythm Pharmaceuticals, Inc.	2021-12-10	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Setmelanotide (RM-493) MC4R agonist

Chemical Structure

Molecular Weight: 1117.31